Clinical Trials Logo
  1. Home
  2. Peyronie's Disease
  3. NCT02267460

An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease

Peyronie's Disease Clinical Trial

Official title:
A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease

Clinical Trial Summary

Enrollment will include approximately 30 AA4500 naïve subjects. Subjects will be divided by degree of penile curvature and then randomized in a 1:1 ratio to one of the following treatment groups:

- AA4500 with investigator modeling

- AA4500 without investigator modeling

Each subject will receive 2 injections of AA4500, separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles.

Approximately 14 days after the second injection of AA4500, each subject will visit the study site and the investigator will assess the subject and instruct the subject on appropriate use of the ErecAid® Esteem® Manual Vacuum Therapy System.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02267460
Study type Interventional
Source Endo Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date October 2014
Completion date March 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01685437 - A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Phase 3
Completed NCT01430169 - Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Phase 2
Completed NCT01221597 - Study of AA4500 in the Treatment of Peyronie's Disease Phase 3
Recruiting NCT05108558 - Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders Phase 4
Recruiting NCT05147779 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Phase 1
Recruiting NCT03767452 - Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Phase 4
Completed NCT01221623 - Study of AA4500 in the Treatment of Peyronie's Disease Phase 3
Completed NCT02298829 - Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Completed NCT01243411 - A Study of AA4500 in Men With Peyronie's Disease Phase 3
Completed NCT01578473 - Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Phase 1
Not yet recruiting NCT05855070 - Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease N/A
Completed NCT02072018 - Peyronie's Disease Treatment Protocol Phase 1
Terminated NCT05873595 - Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
Active, not recruiting NCT04786106 - Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's Phase 4
Completed NCT00812838 - H-22411: BOTOX® for Peyronie's Disease Phase 2
Completed NCT02395029 - Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Phase 1
Completed NCT00755222 - The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Phase 2